



AT THE HELM Larry Mickelberg, president

PERFORMANCE

A fourth straight year of growth, and 2013 is projected to be "even better"

HIGHLIGHTS

Merger gives Havas digital "lighthouse" of presence in both European market and the Americas

Tech platforms developed in-house now account for a quarter of agency business

CHALLENGES

Lost work for two developmental products that didn't meet endpoints

For contact details, service offerings and client roster, see Agency A-to-Z, beginning on page 187

"We sense an opportunity to create a new kind of consumer health agency"

-Larry Mickelberg

Havas Lynx

For growing Havas digital shop, "mobile is really where it's at"



pharmaceutical products, and so they're looking at both the molecule and the molecule-plus-diagnostic to see what the delta is in terms of outcomes, and what they're finding is really exciting."


And with that, the nature of the marketing business is changing as well. "In the old days, we were doing advertising. We pushed a message. Now we provide value-added services and support, we do what we call service-driven design, which is taking a robust understanding of the customer, whether consumer or HCP, marrying that with our expert knowledge of the channels to create really differentiated experiences that people can have with these products."

They're also investing in their own tech platforms that they license out to clients. They launched Virtual Environment, a 3D-rendered environment used for training, back in 2008, and more recently released a proprietary e-detailing platform called Profile. A companion remote-detailing product, code-named Correspondence, is in development.

AS YOUR PROSTATE, I'VE GOTTA TELL YOU: WAKING UP TO "GO" IS EXHAUSTING! Mickelberg says such platforms are about a quarter of the shop's business. "It's a place where we're really investing and one where I think all agencies have to play. We like to play in the content business as

agencies, but it's nice when you can actually manage both the content and the channel."


The shop had its fourth straight year of growth, despite the loss last summer of two developmental products that failed to meet their endpoints. So far,



Havas Lynx's role in Havas has been as technological "lighthouse," says Mickelberg. It's their job to push the envelope, to peer into the future. So what's new?

"For almost every client, we're designing a mobilefirst strategy," says Mickelberg. "The desktop is not necessarily an afterthought, but for our clients, mobile is really where it's at."

That shift is happening in tandem with the arrival of a post-pill business. "Many of our clients have in clinical trials sensors and devices as companions to



Havas Lynx work for the BPH medication Rapaflo (above left) and Sanofi Diabetes (above)

2013 is looking "even better from a growth perspective."

Going forward, Mickelberg expects the network to do a lot more consumer work. "We sense an opportunity to create a new kind of consumer health agency," he says. "Today, we work in biopharma, in devices and diagnostics. Over time, we'll expand into ancillary businesses like healthy living, gyms and spas, retail health and consumer products." – Matthew Arnold